BURNABY, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report exciting survival data using a combination of Qu Biologics’ QBECO SSI and CAR T-cell therapy in laboratory models of aggressive cancer. The study was conducted in collaboration with the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine).
